Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Yaling An und 17 weiteren Autor:innen. Beteiligte Einrichtung: Savaid Medical School, University of Chinese Academy of Sciences (UCAS), Beijing, China. Hauptthemen laut MEDLINE: COVID-19, Vaccines, DNA, Viral Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Chinese Academy of Sciences, Bill and Melinda Gates Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID‐19) pandemic posed great impacts on public health. To fight against the pandemic, robust immune responses induced by vaccination are indispensable. Previously, we developed a subunit vaccine adjuvanted by aluminum hydroxide, ZF2001, based on the dimeric tandem‐repeat RBD immunogen, which has been approved for clinical use. This dimeric RBD design was also explored as an mRNA vaccine. Both showed potent immunogenicity. In this study, a DNA vaccine candidate encoding RBD‐dimer was designed. The humoral and cellular immune responses induced by homologous and heterologous prime‐boost approaches with DNA‐RBD‐dimer and ZF2001 were assessed in mice. Protection efficacy was studied by the SARS‐CoV‐2 challenge. We found that the DNA‐RBD‐dimer vaccine was robustly immunogenic. Priming with DNA‐RBD‐dimer followed by ZF2001 boosting induced higher levels of neutralizing antibodies than homologous vaccination with either DNA‐RBD‐dimer or ZF2001, elicited polyfunctional cellular immunity with a T H 1‐biased polarization, and efficiently protected mice against SARS‐CoV‐2 infection in the lung. This study demonstrated the robust and protective immune responses induced by the DNA‐RBD‐dimer candidate and provided a heterologous prime‐boost approach with DNA‐RBD‐dimer and ZF2001.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Savaid Medical School, University of Chinese Academy of Sciences (UCAS), Beijing, China.
- Advaccine Biopharmaceutics (Suzhou) Co. Ltd, Suzhou, China.
- CAS Key Laboratory of Pathogen Microbiology and Immunology, Chinese Academy of Sciences (CAS), Beijing, China.
- School of Life Sciences, Yunnan University, Kunming, China.
- School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: George F Gao
Förderung
- Chinese Academy of Sciences
- Bill and Melinda Gates Foundation
- National Natural Science Foundation of China
Zitieren
APA
An, Y., Zhao, G., Duan, H., Zhang, N., Duan, M., Xu, S., Liu, X., Han, Y., Zheng, T., Li, X., Hou, J., Zhang, Z., Bi, Y., Zhao, X., Xu, K., Dai, L., Wang, B., & Gao, G. F. (2023). Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19. Journal of Medical Virology. https://doi.org/10.1002/jmv.28948
Vancouver
An Y, Zhao G, Duan H, Zhang N, Duan M, Xu S, et al. Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19. Journal of Medical Virology. 2023. doi:10.1002/jmv.28948
BibTeX
@article{An2023,
author = {An, Yaling and Zhao, Gan and Duan, Huixin and Zhang, Ning and Duan, Minrun and Xu, Senyu and Liu, Xueyuan and Han, Yuxuan and Zheng, Tianyi and Li, Xin and Hou, Jiawang and Zhang, Zhiyu and Bi, Yuhai and Zhao, Xin and Xu, Kun and Dai, Lianpan and Wang, Bin and Gao, George F},
title = {Robust and protective immune responses induced by heterologous prime‐boost vaccination with DNA‐protein dimeric RBD vaccines for COVID‐19},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28948}
}
EUVIMED